Skip to main content
All lobbying filings

DLA PIPER LLP (US)

Lobbying for BIOGEN, INC. · Biotechnology company.

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • RACHEL PORTMAN New on this filing
    Previously held: Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman
  • MAREN MCBRIDE New on this filing
    Previously held: Counsel, Rep. Mollohan

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4
  • Centers For Medicare and Medicaid Services (CMS)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 6
Health Issues

Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.

Taxation/Internal Revenue Code

Issues related to tax reform.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property.

Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.

Copyright/Patent/Trademark

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem